Roles of human liver type fatty acid binding protein in kidney disease clarified using hL-FABP chromosomal transgenic mice

Nephrology

Volumn 16, Issue 6, 2011, Pages 539-544

  Kamijo Ikemori, Atsuko ^a   Sugaya, Takeshi ^a   Matsui, Katsuomi ^a   Yokoyama, Takeshi ^a   Kimura, Kenjiro ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

fatty acid binding protein; kidney disease; renal protection; Tg mouse; tubulointerstitial damage

Indexed keywords

ALLOPURINOL; ALPHA SMOOTH MUSCLE ACTIN; BIOCHEMICAL MARKER; CISPLATIN; FATTY ACID BINDING PROTEIN; LIVER TYPE FATTY ACID BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; XANTHINE DEHYDROGENASE INHIBITOR; XANTHINE OXIDASE INHIBITOR;

ACUTE ISCHEMIA REPERFUSION; ACUTE KIDNEY FAILURE; ADENINE INDUCED NEPHROPATHY; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERY CLAMP; CHRONIC KIDNEY DISEASE; CISPLATIN INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; EXPERIMENTAL STUDY; GENE ACTIVATION; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; MACROPHAGE MIGRATION INHIBITION; NEOPLASM; NONHUMAN; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN OVERLOAD NEPHORPATHY; PROTEIN URINE LEVEL; REVIEW; STREPTOZOCIN DIABETES; TRANSGENIC MOUSE; UNILATERAL URETERAL OBSTRUCTION; UPREGULATION; URETER LIGATION;

ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FATTY ACID-BINDING PROTEINS; HUMANS; KIDNEY DISEASES; KIDNEY TUBULES, PROXIMAL; MICE; MICE, TRANSGENIC;

EID: 80051702340     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2011.01469.x     Document Type: Review

References (30)

1. Sarnak MJ, Levey AS, Schoolwerth AC, et al,. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-69. (Pubitemid 37337595)
2. Nakayama M, Metoki H, Terawaki H, et al,. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population-The Ohasama study. Nephrol. Dial. Transplant. 2007; 22: 1910-15. (Pubitemid 47244759)
3. Risdon RA, Sloper JC, De Wardener HE,. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 1968; 2: 363-66.
4. Walker PD, Shah SV,. Evidence suggesting a role for hydroxyl radical in gentamicin-induced acute renal failure in rats. J. Clin. Invest. 1988; 81: 334-41. (Pubitemid 18075224)
5. Portilla D, Li S, Nagothu KK, et al,. Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int. 2006; 69: 2194-204. (Pubitemid 43882106)
6. Portilla D, Shah SV, Lehman PA, Creer MH,. Role of cytosolic calcium-independent plasmalogen-selective phospholipase A2 in hypoxic injury to rabbit proximal tubules. J. Clin. Invest. 1994; 93: 1609-15. (Pubitemid 24116399)
7. Kamijo Y, Hora K, Tanaka N, et al,. Identification of functions of peroxisome proliferator-activated receptor alpha in proximal tubules. J. Am. Soc. Nephrol. 2002; 13: 1691-702. (Pubitemid 34700593)
8. Kamijo A, Kimura K, Sugaya T, et al,. Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int. 2002; 62: 1628-37. (Pubitemid 35286270)
9. Maatman RG, van de Westerlo EM, van Kuppevelt TH, Veerkamp JH,. Molecular identification of the liver- and the heart-type fatty acid-binding proteins in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction. Biochem. J. 1992; 288: 285-90.
10. Veerkamp JH, van Kuppevelt TH, Maatman RG, Prinsen CF,. Structural and functional aspects of cytosolic fatty acid-binding proteins. Prostaglandins Leukot. Essent. Fatty Acids 1993; 49: 887-906. (Pubitemid 24027467)
11. Wang G, Gong Y, Anderson J, et al,. Antioxidative function of L-FABP in L-FABP stably transfected Chang liver cells. Hepatology 2005; 42: 871-79. (Pubitemid 41401125)
12. Kamijo A, Kimura K, Sugaya T, et al,. Urinary fatty acid binding protein as a new clinical marker for the progression of chronic renal disease. J. Lab. Clin. Med. 2004; 143: 23-30. (Pubitemid 38156413)
13. Kamijo A, Sugaya T, Hikawa A, et al,. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am. J. Pathol. 2004; 165: 1243-55. (Pubitemid 39297730)
14. Remuzzi G, Benigni A, Remuzzi A,. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J. Clin. Invest. 2006; 116: 288-96. (Pubitemid 43228342)
15. Remuzzi G, Bertani T,. Pathophysiology of progressive nephropathies. N. Engl. J. Med. 1998; 339: 1448-56. (Pubitemid 28516069)
16. Kamijo A, Sugaya T, Hikawa A, et al,. Clinical evaluation of urinary excretion of liver-type fatty acid binding protein as a marker for monitoring chronic kidney disease: A multi-center trial. J. Lab. Clin. Med. 2005; 145: 125-33. (Pubitemid 40432361)
17. Kamijo-Ikemori A, Sugaya T, Yasuda T, et al,. Clinical significance of urinary liver-type fatty acid binding protein in diabetic nephroptahy of type 2 diabetic patients. Diabetes Care 2011; 34: 691-6.
18. Nielsen SE, Sugaya T, Tarnow L, et al,. Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care 2009; 32: 1684-88.
19. Nangaku M,. Chronic hypoxia and tubulointerstitial injury: A final common pathway to end-stage renal failure. J. Am. Soc. Nephrol. 2006; 17: 17-25.
20. Ferguson MA, Vaidya VS, Waikar SS, et al,. Urinary liver-type fatty acid-binding protein predicts adverse outcomes in acute kidney injury. Kidney Int. 2010; 77: 708-14.
21. Portilla D, Dent C, Sugaya T, et al,. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2008; 73: 465-72. (Pubitemid 351186293)
22. Kamijo-Ikemori A, Sugaya T, Obama A, et al,. Liver type fatty acid binding protein attenuates renal injury induced by unilateral ureteral obstruction. Am. J. Pathol. 2006; 169: 1107-17. (Pubitemid 351194349)
23. Tanaka T, Doi K, Maeda-Mamiya R, et al,. Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury. Am. J. Pathol. 2009; 174: 1203-11.
24. Kamijo-Ikemori A, Sugaya T, Sekizuka A, et al,. Amelioration of diabetic tubulointerstitial damage in liver-type fatty acid-binding protein transgenic mice. Nephrol. Dial. Transplant. 2009; 24: 788-800.
25. Yamamoto T, Noiri E, Ono Y, et al,. Renal L-type fatty acid-Binding protein in acute ischemic injury. J. Am. Soc. Nephrol. 2007; 18: 2894-902. (Pubitemid 350058396)
26. Negishi K, Noiri E, Maeda R, et al,. Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury. Kidney Int. 2008; 73: 1374-84. (Pubitemid 351770480)
27. Negishi K, Noiri E, Sugaya T, et al,. A role of liver fatty acid-binding protein in cisplatin-induced acute renal failure. Kidney Int. 2007; 72: 348-58. (Pubitemid 47172375)
28. Yokoyama T, Kamijo-Ikemori A, Sugaya T, et al,. Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage. Am. J. Pathol. 2009; 174: 2096-106.
29. Ninichuk V, Kulkarni O, Clauss S, Anders HJ,. Tubular atrophy, interstitial fibrosis, and inflammation in type 2 diabetic db/db mice. An accelerated model of advanced diabetic nephropathy. Eur. J. Med. Res. 2007; 12: 351-55. (Pubitemid 47365152)
30. Wolfrum C, Borrmann CM, Borchers T, Spener F,. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha-and gamma-mediated gene expression via liver fatty acid binding protein: A signaling path to the nucleus. Proc. Natl Acad. Sci. USA 2001; 98: 2323-28. (Pubitemid 32209481)